skip to Main Content

New Paradigm for Drug Toxicity

PRODUCTS

Introducing NEXEL’s products

Cardiosight®-S

Explore Cardiac Toxicity with Human induced Pluripotent Stem Cell (iPSC)-derived cardiomyocytes.

Cardiovascular disease is the most common cause of death around the world, accounting for estimated death of 17.7 million (WHO, 2017). The disease is the result of combinations of various factors including genetic or physiological conditions, as well as adverse drug reactions. In fact, the cardiotoxicity is common causes of withdrawal of the newly developed drugs from the market.

Using NEXEL’s novel hiPSC-derived cardiomyocytes, better prediction of human cardiotoxicity can be achieved compared to traditional animal models. Therefore, using Cardiosight®-S can substitute costly animal models and enables pharmaceutical industry to test cardiotoxicity in a more affordable fashion.

Applications of Cardiosight®-S

Cardiosight-S® can be used for various applications such as:

1. Cardiotoxicity testing
2. Drug discovery
3. Electrophysiological and biochemical assay

Products

NEXEL offers the Cardiosight®-S in cryopreserved vials of 2 million or 5 million cells, which are terminally differentiated functional cardiomyocytes. Cardiosight®-S have been validated in a variety of applications. Please enquire for any technical guidance or questions.

The latest version of the User Guide can be downloaded here.

Catalog number C-001
Description
Cryopreserved Cardiosight®-S

Each kit contains

1. Cardiosight®-S Media (CM-001, 50 ml)
2. Cardiosight®-S Supplement (CS-001, 1 ml)
3. Cardiosight®-S User Guide

Quantity ≥ 2 × 106 Viable cells/Vial
Request Quote
Catalog number C-002
Description
Cryopreserved Cardiosight®-S

Each kit contains

1. Cardiosight®-S Media (CM-002, 100 ml)
2. Cardiosight®-S Supplement (2x CS-001, 2x 1 ml)
3. Cardiosight®-S User Guide

Quantity ≥ 5 × 106 Viable cells/Vial
Request Quote
Back To Top